Influenza Vaccines: Global Markets

Report Highlights

The global influenza vaccines market is estimated to increase from $6.9 billion in 2021 to $10.1 billion by 2026, at a compound annual growth rate (CAGR) of 7.9% during the forecast period of 2021-2026.

Report Includes

• 20 data tables and 29 additional tables
• An updated overview of the global market for influenza vaccines within the biopharmaceutical industry
• Analyses of the global market trends, with historic revenue (sales) data for 2019-2021, and projections of compound annual growth rates (CAGRs) through 2026
• Evaluation and forecast the market size for influenza vaccines, and corresponding market share analysis by type, technology, age, and region
• Information on baloxavir marboxil (Xofluza) vaccine, along with types of influenza virus strains used for vaccine preparation like influenza type A with H3N2 virus strain, influenza type A with H1N1 virus strain, and influenza type B virus strain
• Country specific data and market value analysis for the U.S., Canada, Germany, U.K., France, Italy, Spain, Australia, Japan, China and India
• Technology assessment of the key drivers, restraints and opportunities that will shape the market over the next five years (2021 to 2026)
• Discussion of technology advancements in influenza vaccines development, product innovations, government regulations, clinical trials, and other key market strategies
• Coverage of key merger acquisition strategies and collaboration agreements in the marketplace
• In-depth information on increasing investments on R&D activities, key technology issues, industry specific challenges, major types of end-user markets, and COVID-19 implications on the progress of this market
• Descriptive company profiles of the leading global players, including AstraZeneca, CSL Ltd., Abbott Laboratories, GlaxoSmithKline plc and Sanofi

Report Scope

The report explains critical trends in the influenza vaccine industry. It discusses the market determinants, which act as motivating or restraining factors, and provides insights to stakeholders and potential entrants.

This report study includes only human vaccines; animal vaccines have not been considered in this report.

This study looks at most of the systems affected by factors such as considerable research and development spending and increasing competition and new technologies, which are giving direction to the market. These advancements, new product launches and changing lifestyles are influencing future market growth.

Company merger acquisition strategies and collaborations are also covered in this report. Additionally, this study discusses the strengths and weaknesses of each strategy type considering new technologies, growing competition and changing customer needs.

The market has also been analyzed based on the type of influenza vaccines. Categories considered in this report include inactivated vaccines and live-attenuated vaccines.

This study details market growth among vaccine manufacturers and end users. Genomic research centers, academic institutions, government and private laboratories and various hospital settings, as well as pharmaceutical, diagnostic and biotechnology companies and physicians, will find this study to be of interest.

The report provides useful information to all market players, potential entrants, government agencies and other interested parties. As the report covers geographic regions in detail, companies interested in expanding their geographic reach will also find this study useful.

Analyst Credentials

BCC Publishing Staff comprises expert analysts who are skilled in conducting primary research, secondary research and data analysis and have decades of combined experience covering a wide range of industries, including healthcare, advanced materials and emerging technologies. Collectively, the team represents a diverse set of educational achievements with individual graduate work completed in fields such as microbiology, electrical engineering, business administration and surgery, among others.